Seek Returns

BIO.B vs. ZTS: Bio-Rad Laboratories vs. Zoetis Stock Comparison

How do Bio-Rad Laboratories (BIO.B) and Zoetis (ZTS) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Bio-Rad Laboratories (BIO.B) and Zoetis (ZTS) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but BIO.B is classified in Life Sciences Tools & Services while ZTS is classified in Pharmaceuticals.

Company profile comparison for Bio-Rad Laboratories (BIO.B) and Zoetis (ZTS)
Profile ItemBIO.BZTS
NameBio-Rad Laboratories, Inc. Class B Common StockZoetis Inc. Class A Common Stock
Country/RegionUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS Industry GroupPharmaceuticals, Biotechnology & Life SciencesPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & ServicesPharmaceuticals
GICS Sub-IndustryLife Sciences Tools & ServicesPharmaceuticals
Market Capitalization10.49 billion USD32.26 billion USD
CurrencyUSDUSD
ExchangeNYSENYSE
Listing DateSeptember 21, 1999February 1, 2013
Security TypeCommon StockCommon Stock

Price Performance

Cumulative Growth

BIO.B
ZTS
GSPC
Loading price history…
Bio-Rad Laboratories (BIO.B) vs. Zoetis (ZTS), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…
Trailing total returns for Bio-Rad Laboratories (BIO.B) and Zoetis (ZTS). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…
Calendar-year total returns for Bio-Rad Laboratories (BIO.B) and Zoetis (ZTS). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Bio-Rad Laboratories (BIO.B) and Zoetis (ZTS)
MetricBIO.BZTS
Total Return (1Y)27.69%-30.10%
Total Return (3Y, Annualized)9.13%-20.42%
Total Return (5Y, Annualized)-12.33%-16.87%

Risk Profile

Drawdown History

BIO.B
ZTS
GSPC
Loading price history…
Bio-Rad Laboratories (BIO.B) vs. Zoetis (ZTS), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…
Distribution of monthly total returns for Bio-Rad Laboratories (BIO.B) and Zoetis (ZTS). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Zoetis (ZTS) trades around 4.65M shares per day on average, while Bio-Rad Laboratories (BIO.B) sees only 11 — a volume gap that can matter for position sizing, exit liquidity, and order execution.

Risk profile metrics for Bio-Rad Laboratories (BIO.B) and Zoetis (ZTS)
MetricBIO.BZTS
Volatility (1Y, Annualized)30.96%38.23%
Beta (5Y)1.000.66
Max Drawdown (5Y)-70.74%-70.45%
Avg. Volume (3M)114.65M

Risk-Adjusted Performance

Risk-Return Positioning

Loading chart…
BIO.B and ZTS are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Bio-Rad Laboratories (BIO.B) and Zoetis (ZTS)
MetricBIO.BZTS
Sharpe Ratio (1Y)0.74-0.90
Sortino Ratio (1Y)1.10-1.10

Profitability

ROE (TTM)

Both Bio-Rad Laboratories (BIO.B) at 14.27% and Zoetis (ZTS) at 57.63% sit in the top peer quartile for ROE, suggesting each generates more profit from shareholders’ equity than typical industry peers.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

14.27%

Max
109.18%
BIO.B
14.27%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

57.63%

Max
109.18%
ZTS
57.63%
Q3
6.23%
Median
-26.66%
Q1
-64.05%
Min
-167.77%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Zoetis (ZTS): A comparison of their ROE against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Net Margin (TTM)

Both Bio-Rad Laboratories (BIO.B) at 39.45% and Zoetis (ZTS) at 26.41% keep an unusually large share of revenue as bottom-line profit — each net margin clears its industry’s benchmark range.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

39.45%

BIO.B
39.45%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

26.41%

ZTS
26.41%
Max
18.05%
Q3
4.78%
Median
0.00%
Q1
-4.14%
Min
-17.05%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Zoetis (ZTS): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Zoetis (ZTS) at 38.19% operates in the top operating margin quartile, ahead of Bio-Rad Laboratories (BIO.B) at 9.46%, which runs around its industry’s norm.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.46%

Max
83.12%
Q3
14.77%
BIO.B
9.46%
Median
0.00%
Q1
-78.82%
Min
-207.40%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

38.19%

Max
83.12%
ZTS
38.19%
Q3
14.77%
Median
0.00%
Q1
-78.82%
Min
-207.40%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Zoetis (ZTS): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Bio-Rad Laboratories (BIO.B) and Zoetis (ZTS)
MetricBIO.BZTS
ROE (TTM)14.27%57.63%
ROA (TTM)1.50%14.87%
Net Margin (TTM)39.45%26.41%
Operating Margin (TTM)9.46%38.19%
Gross Margin (TTM)52.19%71.65%

Growth

Revenue Growth

Both Bio-Rad Laboratories (BIO.B) at 0.65% and Zoetis (ZTS) at 2.28% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Zoetis (ZTS): A comparison of their Revenue Growth across different time periods.

EPS Growth

Only one side can be read here: Zoetis (ZTS) reports EPS growth of 10.05%, ranked against its industry; Bio-Rad Laboratories (BIO.B) has no EPS growth figure this period.

Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Zoetis (ZTS): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Bio-Rad Laboratories (BIO.B) and Zoetis (ZTS)
MetricBIO.BZTS
Revenue Growth (YoY)0.65%2.28%
Revenue Growth (3Y CAGR)-2.68%5.42%
EPS Growth (YoY)--10.05%
EPS Growth (3Y CAGR)--10.27%

Financial Strength

Current Ratio (MRQ)

Bio-Rad Laboratories (BIO.B) at 3.18 keeps current ratio within its industry’s typical mid-range, while Zoetis (ZTS) at 2.35 runs in the tighter-liquidity quartile — a thinner cushion against current liabilities for ZTS.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.18

Max
25.13
Q3
12.13
Median
5.52
BIO.B
3.18
Q1
2.47
Min
0.10

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.35

Max
25.13
Q3
12.13
Median
5.52
Q1
2.47
ZTS
2.35
Min
0.10
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Zoetis (ZTS): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Bio-Rad Laboratories (BIO.B) at 0.18 is near its industry mid-range for debt-to-equity ratio, while Zoetis (ZTS) at 2.80 sits above its benchmark range, pointing to a heavier debt load relative to equity.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.18

Max
1.42
Q3
0.65
BIO.B
0.18
Median
0.15
Q1
0.02
Min
0.00

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.80

ZTS
2.80
Max
1.42
Q3
0.65
Median
0.15
Q1
0.02
Min
0.00
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Zoetis (ZTS): A comparison of their debt-to-equity ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Financial Strength Metrics

Financial strength metrics for Bio-Rad Laboratories (BIO.B) and Zoetis (ZTS)
MetricBIO.BZTS
Current Ratio (MRQ)3.182.35
Debt / Equity (MRQ)0.182.80
Net Debt / EBITDA-0.731.92

Dividends

Dividend Yield (TTM)

Bio-Rad Laboratories (BIO.B) pays no dividend (yield 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Zoetis (ZTS) reports a yield of 2.55%, ranking against industry peers normally.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIO.B
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.55%

ZTS
2.55%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Zoetis (ZTS): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

Bio-Rad Laboratories (BIO.B) pays no dividend (payout 0.00%) — it may be reinvesting, using buybacks, or simply not returning cash through dividends. Meanwhile Zoetis (ZTS) reports a payout of 35.24%, ranking against industry peers normally.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.00%

BIO.B
0.00%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

35.24%

ZTS
35.24%
Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Zoetis (ZTS): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Bio-Rad Laboratories (BIO.B) and Zoetis (ZTS)
MetricBIO.BZTS
Dividend Yield (TTM)0.00%2.55%
Dividend Payout Ratio (TTM)0.00%35.24%

Valuation

P/E Ratio (TTM)

Bio-Rad Laboratories (BIO.B) at 10.36 sits in the cheaper P/E ratio quartile, while Zoetis (ZTS) at 13.50 is closer to its industry’s usual earnings multiple — a discount for BIO.B, though growth and earnings durability still matter.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

10.36

Max
85.34
Q3
43.46
Median
26.69
Q1
13.30
BIO.B
10.36
Min
0.07

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

13.50

Max
85.34
Q3
43.46
Median
26.69
ZTS
13.50
Q1
13.30
Min
0.07
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Zoetis (ZTS): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Bio-Rad Laboratories (BIO.B) at 4.05 and Zoetis (ZTS) at 3.40 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

4.05

Max
58.18
Q3
25.77
Median
7.30
BIO.B
4.05
Q1
3.01
Min
0.01

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

3.40

Max
58.18
Q3
25.77
Median
7.30
ZTS
3.40
Q1
3.01
Min
0.01
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Zoetis (ZTS): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

Bio-Rad Laboratories (BIO.B) at 1.38 looks cheap against book in the lower P/B ratio quartile, while Zoetis (ZTS) at 9.80 carries a premium in the upper quartile — a clear price-to-book gap.

BIO.B

Pharmaceuticals, Biotechnology & Life Sciences industry group

1.38

Max
13.53
Q3
6.54
Median
3.25
Q1
1.69
BIO.B
1.38
Min
-5.59

ZTS

Pharmaceuticals, Biotechnology & Life Sciences industry group

9.80

Max
13.53
ZTS
9.80
Q3
6.54
Median
3.25
Q1
1.69
Min
-5.59
Loading chart…
Bio-Rad Laboratories (BIO.B) vs. Zoetis (ZTS): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Bio-Rad Laboratories (BIO.B) and Zoetis (ZTS)
MetricBIO.BZTS
P/E Ratio (TTM)10.3613.50
P/S Ratio (TTM)4.053.40
P/B Ratio (MRQ)1.389.80
Free Cash Flow Yield (TTM)2.59%6.36%